JAGUAR HEALTH INC (JAGX) Stock News

NASDAQ:JAGX - Nasdaq - US47010C8055 - Common Stock

0.8301 -0.01 (-1.23%)

JAGX Latest News and Analysis

All

Press Releases

3 hours ago - ACCESS Newswire

Jaguar Health Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Crofelemer for the Rare Disease Indication of Microvillus Inclusion Disease (MVID), with Proof-of-Concept (POC) Data Potentially Available H1 2025

12 days ago - ACCESSWIRE

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 days ago - ACCESSWIRE

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

15 days ago - ACCESSWIRE

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

a month ago - ACCESSWIRE

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

a month ago - ACCESSWIRE

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

a month ago - ACCESSWIRE

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

a month ago - ACCESSWIRE

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

a month ago - ACCESSWIRE

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

a month ago - ACCESSWIRE

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

2 months ago - ACCESSWIRE

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

2 months ago - ACCESSWIRE

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

2 months ago - ACCESSWIRE

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

2 months ago - ACCESSWIRE

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

2 months ago - ACCESSWIRE

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

2 months ago - ACCESSWIRE

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

2 months ago - Benzinga

Earnings Scheduled For November 13, 2024

2 months ago - ACCESSWIRE

Jaguar Health Reports Third Quarter 2024 Financial Results

2 months ago - Benzinga

Exploring Jaguar Health's Earnings Expectations

2 months ago - ACCESSWIRE

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

3 months ago - ACCESSWIRE

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

3 months ago - ACCESSWIRE

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

3 months ago - ACCESSWIRE

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

3 months ago - ACCESSWIRE

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

3 months ago - ACCESSWIRE

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - ACCESSWIRE

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

4 months ago - ACCESSWIRE

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

4 months ago - ACCESSWIRE

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

4 months ago - ACCESSWIRE

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and

4 months ago - ACCESSWIRE

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

4 months ago - ACCESSWIRE

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

4 months ago - ACCESSWIRE

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

4 months ago - ACCESSWIRE

Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

5 months ago - ACCESSWIRE

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

5 months ago - ACCESSWIRE

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

5 months ago - ACCESSWIRE

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones

5 months ago - ACCESSWIRE

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

5 months ago - ACCESSWIRE

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

5 months ago - ACCESSWIRE